ASPC 2018 Congress on CVD Prevention
Avatar

Comprehensive Approach to Lowering CVD Risk in Diabetics

By ASPC 2018 Congress on CVD Prevention FEATURING Yehuda Handelsman
August 10, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

19:47
Novo Nordisk – GLP-1 RA Therapy

GLP-1 RA Use in Clinical Practice: Examining Trial Data and T2D Trea…

Feat. L. Coco, C. Solis-Herrera

Featured Video

07:57
Novartis Cardiology

Clinical Trial Data Overview: LDL-C Reduction in Patients with ASCVD…

Feat. A. Brown

Related Content

AUTOPLAY
06:38
Allan Jaffe

What Does Elevated Troponin Mean in COVID-19?

16:57
William White

Ambulatory Blood Pressure Monitoring

64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
47:11
Houston Methodist Hospital

The Protein Myth: Our Obsession With Protein and How It Is Killing US

Feat. G. Davis
17:21
Ilene Fennoy

Obesity and Diabetes in Children

28:13
National Lipid Association

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

Feat. R. Mason
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
10:12
AHA 2022 Conference Coverage

AHA 2022: Chlorthalidone Compared to Hydrochlorothiazide for the Pre…

Feat. A. Ishani
26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

10:41
Houston Methodist DeBakey Heart and Vascular Center

2020 High Blood Pressure Guidelines: When Is BP Too High?

Feat. A. Marie Navar
45:45
Houston Methodist DeBakey Heart and Vascular Center

Directions of Cardiology in the Next Decade: 2022-2032

Feat. E. Braunwald
17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
20:24
Diana Isaacs

Tirzepatide for Type 2 Diabetes

15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

42:27
Physicians Committee for Responsible Medicine

Hypertension Management & Nutrition: What Are the Key Nutrients …

Feat. V. Rahman